Drug Discover Groups Recompetition Approved, But Advisors Scale Back Model Development
In Brief: NCI Scientist Accused Of Taking ‘Payoffs’ Forom Drug Firms; GM-CS Wins FDA Approval
DCT Advisors OK Recompetition Of Drug Contacts
ICCCR Participants Honor Cullen, Blast Tobacco Industry
Gallo Publishes Study to Resolve controversy Over HIV Discovery
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research









